Onconetix, Inc. (ONCO): Gross Profit
$632.9K
Year ended 2025-12-31
$519.2K
Trailing 12 months to 2026-06-30
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $632.9K | -40.0% | 2026-03-13, From 2025-01-01 |
| 2024-12-31 | $1.06M | n/m | 2026-03-13, From 2024-01-01 |
| 2023-12-31 | -$1.13M | n/a | 2025-06-02, From 2023-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | 2025-12-31 | $632.9K | -40.0% |
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $703.2K | +53.1% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $223.8K | +0.4% |
| Polomar Health Services, Inc. (PMHS) | 2025-12-31 | $460.1K | n/m |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $734.4K | n/a |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $478.0K | +288.6% |
| Bespoke Extracts, Inc. (BSPK) | 2024-12-31 | $452.9K | +32.0% |
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $185.3K | n/a |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | $248.7K | -32.3% |
Compare ONCO, LEXX, SXTP, PMHS side by side · Screen every company in Pharmaceutical Preparations ↗